Evidence map›Paper›PMID 35425259›Full record

ArticleRSC advances2022

Phenylalanyl tRNA synthetase (PheRS) substrate mimics: design, synthesis, molecular dynamics and antimicrobial evaluation.

Nada A Noureldin, Jennifer Richards, Hend Kothayer, Mohammed M Baraka, Sobhy M Eladl, Mandy Wootton, Claire Simons

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. ExploringPharmaceuticals (Basel, Switzerland) · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Nada A NoureldinSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University Cardiff CF10 3NB UK NANoureddine@pharmacy.zu.edu.eg.ORCID https://orcid.org/0000-0002-8050-9792
Jennifer RichardsSpecialist Antimicrobial Chemotherapy Unit, University Hospital of Wales Heath Park Cardiff CF14 4XW UK.
Hend KothayerDepartment of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University Zagazig P. C. 44519 Egypt.ORCID https://orcid.org/0000-0002-2954-0751
Mohammed M BarakaDepartment of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University Zagazig P. C. 44519 Egypt.
Sobhy M EladlDepartment of Medicinal Chemistry, Faculty of Pharmacy, Zagazig University Zagazig P. C. 44519 Egypt.ORCID https://orcid.org/0000-0003-1490-1953
Mandy WoottonSpecialist Antimicrobial Chemotherapy Unit, University Hospital of Wales Heath Park Cardiff CF14 4XW UK.
Claire SimonsSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University Cardiff CF10 3NB UK NANoureddine@pharmacy.zu.edu.eg.ORCID https://orcid.org/0000-0002-9487-1100
Zagazig University · EGUniversity Hospital of Wales · GBCardiff University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance is a very challenging medical issue and identifying novel antimicrobial targets is one of the means to overcome this challenge. Phenylalanyl tRNA synthetase (PheRS) is a promising antimicrobial target owing to its unique structure and the possibility of selectivity in the design of inhibitors. Sixteen novel benzimidazole based compounds (5a-b), (6a-e), (7a-d), (9a-e) and three

Identifiers

PMID35425259
PMCPMC8979089
OpenAlexW4205854290

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.